Moderna shares slip in premarket after 150% surge
Moderna (MRNA) is trading slightly lower Wednesday morning, with shares down 2.75% to $154.47 in premarket trading after a prior move of more than 150%.
Shares of Moderna Inc. (NASDAQ: MRNA ) are trading slightly lower Wednesday morning, taking a brief pause after surging more than 150% following landmark clinical trial updates for its oncology pipeline.
The modest retreat reflects routine profit-taking and consolidation as investors digest the recent momentum.
Moderna stock is among today’s weakest performers.
Why is MRNA stock falling? Oncology Pipeline Breakthrough Re-Energizes Long-Term Outlook Despite the pullback Wednesday morning, market sentiment surrounding the biotechnology pioneer remains elevated following last week’s historic Phase 3 INTerpath-001 trial results.
Developed in partnership with Merck & Co, Moderna’s individualized mRNA cancer therapy, intismeran (V940/mRNA-4157), combined with Keytruda, demonstrated a statistically significant reduction in melanoma recurrence.
The positive late-stage trial outcome marked the first successful Phase 3 validation for an individualized mRNA cancer treatment, triggering Wall Street price target upgrades and signaling a major strategic transition from pandemic-era vaccine revenues to a broader oncology platform.
MRNA Shares Fall Wednesday Morning MRNA Price Action: Moderna shares were down 2.75% at $154.47 during premarket trading on Wednesday, according to Pro data.
Read Also: Fed's Favorite Inflation Gauge Rises by 3.7% In July, Topping Estimates Image: Shutterstock